The Brugada syndrome: pharmacological therapy.
Atrial fibrillation
Brugada syndrome
Quinidine
Sudden cardiac death
Ventricular arrhythmias
Journal
European heart journal supplements : journal of the European Society of Cardiology
ISSN: 1520-765X
Titre abrégé: Eur Heart J Suppl
Pays: England
ID NLM: 100886647
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
Brugada syndrome is an inherited channelopathy with an increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias (VA) and an increased incidence of supraventricular arrhythmias, as compared with the general population. For the prevention of SCD, the guidelines recommend the implantable cardioverter-defibrillator (ICD); however, ICD does not prevent VA. In this article, we provide a brief review of the literature on the Brugada syndrome pharmacological therapy, mainly focusing on quinidine treatment. The efficacy of quinidine therapy in the prevention of VA in Brugada syndrome has been demonstrated by several small studies in patients with ICD and recurrent shocks or in asymptomatic patients with inducible ventricular fibrillation (VF) at electrophysiological study. Quinidine has also been tested for the prophylaxis of supraventricular arrhythmias, especially atrial fibrillation/flutter, and in paediatric patients. In these studies, quinidine proved highly effective in preventing re-induction of VF and spontaneous recurrences of both ventricular and supraventricular arrhythmias. Unfortunately, this therapy is burdened by a high incidence of side effects, which may lead to drug discontinuation.
Identifiants
pubmed: 37125314
doi: 10.1093/eurheartjsupp/suad036
pii: suad036
pmc: PMC10132564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
C32-C37Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
Heart Rhythm. 2016 Jun;13(6):1274-82
pubmed: 26921764
Heart Rhythm. 2017 Aug;14(8):1147-1154
pubmed: 28411139
Heart Rhythm. 2014 Feb;11(2):259-65
pubmed: 24513919
Circulation. 2005 Feb 8;111(5):659-70
pubmed: 15655131
Circulation. 1999 Oct 12;100(15):1660-6
pubmed: 10517739
Eur Heart J. 2004 May;25(10):879-84
pubmed: 15140537
Circulation. 2006 Nov 28;114(22):2317-24
pubmed: 17116772
Europace. 2014 Apr;16(4):572-7
pubmed: 24068450
Circ Arrhythm Electrophysiol. 2017 May;10(5):e005053
pubmed: 28500178
Circulation. 2004 Sep 28;110(13):1731-7
pubmed: 15381640
J Am Coll Cardiol. 2004 May 19;43(10):1853-60
pubmed: 15145111
Ann Noninvasive Electrocardiol. 2008 Jul;13(3):266-9
pubmed: 18713327
Pacing Clin Electrophysiol. 2009 Mar;32(3):294-301
pubmed: 19272057
Eur Heart J. 2022 Oct 21;43(40):3997-4126
pubmed: 36017572
Pharmacol Res. 2019 Jun;144:257-263
pubmed: 31026503
Europace. 2009 May;11(5):665-6
pubmed: 19346290
Circulation. 1991 Oct;84(4):1831-51
pubmed: 1717173
J Cardiovasc Pharmacol. 2010 Oct;56(4):389-95
pubmed: 20625312
J Am Coll Cardiol. 1996 Apr;27(5):1061-70
pubmed: 8609322
J Cardiovasc Electrophysiol. 2002 Jul;13(7):698-701
pubmed: 12139296
Heart Rhythm. 2007 Jun;4(6):695-700
pubmed: 17556186
Circulation. 2007 Apr 17;115(15):2042-8
pubmed: 17404158
Heart Rhythm. 2012 Dec;9(12):1995-2000
pubmed: 23059185
J Am Coll Cardiol. 2016 Apr 5;67(13):1653-1654
pubmed: 27150692
Eur Heart J. 2006 Jul;27(13):1579-83
pubmed: 16760208
Naunyn Schmiedebergs Arch Pharmacol. 1987 Feb;335(2):216-8
pubmed: 2436062
Heart Rhythm. 2009 Sep;6(9):1335-41
pubmed: 19716089